HealthQuill Pharma
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from the Japanese company.
Drugs Health Pharma

Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million

Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.

Read More
Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to a J&J statement.
Drugs Medical Pharma

Johnson & Johnson to acquire Intra-Cellular Therapies Inc., for $14.6 billion

Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to.

Read More
FDA has granted full approval for Janssen Biotech’s Balversa drug to treat metastatic bladder cancer after clinical trials showed “significant” improvement in overall survival rates.
Drugs Pharma Research

Pfizer’s experimental drug improves survival rates in hard-to-treat bladder cancer

Bharti Jayshankar January 11, 2024: In a breakthrough for bladder cancer treatment, Pfizer’s experimental anti-PD-1 therapy demonstrated superior efficacy compared to the current.

Read More
Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of 30%, according to a Securities and Exchange Commission filing.
Drugs Medical Pharma

Biogen Inc., to buy 62m outstanding shares of Sage for $441.7 million

Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of.

Read More
US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which is under trial, for treating chronic kidney diseases.
Drugs Health Pharma

Vertex, China’s Zai to develop, commercialise kidney disease drug

US-based Vertex Pharmaceutical Inc. has signed a licensing pact with China’s Zai Lab Ltd. to develop and commercialise the Boston-headquartered company’s medicine, which.

Read More
ohnson & Johnson paused its rollout of a heart device to treat atrial fibrillation “out of an abundance of caution,” as it probes four cases of neurovascular events related to the device.
Health Medical Pharma

J&J pauses rollout of heart device in US after ischemic, stroke incidents

ohnson & Johnson paused its rollout of a heart device to treat atrial fibrillation “out of an abundance of caution,” as it probes four.

Read More
China will develop humanoid robots for elderly care and support scientific and technological projects related to senior citizens, according to a state-run news agency.
Health Medical Pharma

China to make humanoid robots, brain-computer interfaces for elderly

China will develop humanoid robots for elderly care and support scientific and technological projects related to senior citizens, according to a state-run news.

Read More
Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more than a year, according to a company statement.
Drugs Health Medical Pharma

J&J’s combination extends lives of cancer patients versus rival drug

Johnson & Johnson’s combination therapy for treating a certain form of cancer without chemotherapy, has been shown to extend patients' lives by more.

Read More
China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight cancer for an upfront payment of $925 million.
Drugs Medical Pharma

WuXi Biologics sells global rights to cancer antibody to Candid for $925m

China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight.

Read More
US-based medical device maker Stryker Corporation will acquire Inari Medical Inc., for about $4.9 billion to expand the former’s neurovascular business.
Drugs Medical Pharma

Stryker to buy Inari for $4.9b to expand neurovascular business

US-based medical device maker Stryker Corporation will acquire Inari Medical Inc., for about $4.9 billion to expand the former’s neurovascular business.

Read More